Ahead of ASCO 2026, abstract “snapshots” released by conference organizers are spotlighting oncology strategies that expand beyond KRAS in pancreatic cancer. Coverage also points to strong interest in multiple modalities—including ADCs, bispecifics, and diagnostics—signaling how trial designs are diversifying across target classes. Separately, a pre-meeting dataset for a TROP2-directed antibody-drug conjugate in non-small cell lung cancer highlighted an early risk-reduction signal when sacituzumab tirumotecan is combined with pembrolizumab. The result feeds expectations around Merck’s growing ADC portfolio, with analysts weighing whether separation translates broadly across subgroups.